Pancreatic Cancer and Obesity: Molecular Mechanisms of Cell Transformation and Chemoresistance

Priscilla Cascetta, Alessandro Cavaliere, Geny Piro, Lorena Torroni, Raffaela Santoro, Giampaolo Tortora, Davide Melisi, Carmine Carbone

Research output: Contribution to journalReview article

Abstract

Cancer and obesity are the two major epidemics of the 21st century. Pancreatic ductal adenocarcinoma (PDAC) is one of the leading causes of death, with a five-year overall survival rate of only 8%. Its incidence and mortality have increased in recent years, and this cancer type is expected to be among the top five leading causes of cancer-related death by 2030 in the United States (US). In the last three decades, the prevalence of overweight people has boosted with a consequent increase in obesity-related diseases. Considerable epidemiologic evidence correlates overweight and obese conditions to an increased risk of several types of cancer, including PDAC. Besides being a risk factor for multiple metabolic disorders, the tumor-promoting effects of obesity occur at the local level via inflammatory mediators that are associated with adipose inflammation and metabolic or hormones mediators and microbiota dysbiosis. Although an excess of body mass index (BMI) represents the second most modifiable risk factor for PDAC with an increased cancer related-death of more than 20⁻40%, still little is known about the molecular mechanisms that underlie this strong association. In this review, we focused on the role of obesity as a preventable risk factor of PDAC, discussing the molecular mechanisms linking obesity to cancer initiation and progression. Moreover, we highlighted the role of obesity in defining chemoresistance, showing how a high BMI can actually reduce response to chemotherapy.

Original languageEnglish
JournalInternational Journal of Molecular Sciences
Volume19
Issue number11
DOIs
Publication statusPublished - Oct 25 2018

Fingerprint

obesity
Pancreatic Neoplasms
Obesity
cancer
Adenocarcinoma
cells
death
Neoplasms
Chemotherapy
Hormones
Body Mass Index
Dysbiosis
Tumors
hormones
causes
mortality
Microbiota
chemotherapy
progressions
Cause of Death

Keywords

  • chemoresistance
  • inflammation
  • obesity
  • pancreatic cancer

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry

Cite this

Pancreatic Cancer and Obesity : Molecular Mechanisms of Cell Transformation and Chemoresistance. / Cascetta, Priscilla; Cavaliere, Alessandro; Piro, Geny; Torroni, Lorena; Santoro, Raffaela; Tortora, Giampaolo; Melisi, Davide; Carbone, Carmine.

In: International Journal of Molecular Sciences, Vol. 19, No. 11, 25.10.2018.

Research output: Contribution to journalReview article

Cascetta, Priscilla ; Cavaliere, Alessandro ; Piro, Geny ; Torroni, Lorena ; Santoro, Raffaela ; Tortora, Giampaolo ; Melisi, Davide ; Carbone, Carmine. / Pancreatic Cancer and Obesity : Molecular Mechanisms of Cell Transformation and Chemoresistance. In: International Journal of Molecular Sciences. 2018 ; Vol. 19, No. 11.
@article{ecc364278eb542a7ae3d60210948f9d9,
title = "Pancreatic Cancer and Obesity: Molecular Mechanisms of Cell Transformation and Chemoresistance",
abstract = "Cancer and obesity are the two major epidemics of the 21st century. Pancreatic ductal adenocarcinoma (PDAC) is one of the leading causes of death, with a five-year overall survival rate of only 8{\%}. Its incidence and mortality have increased in recent years, and this cancer type is expected to be among the top five leading causes of cancer-related death by 2030 in the United States (US). In the last three decades, the prevalence of overweight people has boosted with a consequent increase in obesity-related diseases. Considerable epidemiologic evidence correlates overweight and obese conditions to an increased risk of several types of cancer, including PDAC. Besides being a risk factor for multiple metabolic disorders, the tumor-promoting effects of obesity occur at the local level via inflammatory mediators that are associated with adipose inflammation and metabolic or hormones mediators and microbiota dysbiosis. Although an excess of body mass index (BMI) represents the second most modifiable risk factor for PDAC with an increased cancer related-death of more than 20⁻40{\%}, still little is known about the molecular mechanisms that underlie this strong association. In this review, we focused on the role of obesity as a preventable risk factor of PDAC, discussing the molecular mechanisms linking obesity to cancer initiation and progression. Moreover, we highlighted the role of obesity in defining chemoresistance, showing how a high BMI can actually reduce response to chemotherapy.",
keywords = "chemoresistance, inflammation, obesity, pancreatic cancer",
author = "Priscilla Cascetta and Alessandro Cavaliere and Geny Piro and Lorena Torroni and Raffaela Santoro and Giampaolo Tortora and Davide Melisi and Carmine Carbone",
year = "2018",
month = "10",
day = "25",
doi = "10.3390/ijms19113331",
language = "English",
volume = "19",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
publisher = "MDPI AG",
number = "11",

}

TY - JOUR

T1 - Pancreatic Cancer and Obesity

T2 - Molecular Mechanisms of Cell Transformation and Chemoresistance

AU - Cascetta, Priscilla

AU - Cavaliere, Alessandro

AU - Piro, Geny

AU - Torroni, Lorena

AU - Santoro, Raffaela

AU - Tortora, Giampaolo

AU - Melisi, Davide

AU - Carbone, Carmine

PY - 2018/10/25

Y1 - 2018/10/25

N2 - Cancer and obesity are the two major epidemics of the 21st century. Pancreatic ductal adenocarcinoma (PDAC) is one of the leading causes of death, with a five-year overall survival rate of only 8%. Its incidence and mortality have increased in recent years, and this cancer type is expected to be among the top five leading causes of cancer-related death by 2030 in the United States (US). In the last three decades, the prevalence of overweight people has boosted with a consequent increase in obesity-related diseases. Considerable epidemiologic evidence correlates overweight and obese conditions to an increased risk of several types of cancer, including PDAC. Besides being a risk factor for multiple metabolic disorders, the tumor-promoting effects of obesity occur at the local level via inflammatory mediators that are associated with adipose inflammation and metabolic or hormones mediators and microbiota dysbiosis. Although an excess of body mass index (BMI) represents the second most modifiable risk factor for PDAC with an increased cancer related-death of more than 20⁻40%, still little is known about the molecular mechanisms that underlie this strong association. In this review, we focused on the role of obesity as a preventable risk factor of PDAC, discussing the molecular mechanisms linking obesity to cancer initiation and progression. Moreover, we highlighted the role of obesity in defining chemoresistance, showing how a high BMI can actually reduce response to chemotherapy.

AB - Cancer and obesity are the two major epidemics of the 21st century. Pancreatic ductal adenocarcinoma (PDAC) is one of the leading causes of death, with a five-year overall survival rate of only 8%. Its incidence and mortality have increased in recent years, and this cancer type is expected to be among the top five leading causes of cancer-related death by 2030 in the United States (US). In the last three decades, the prevalence of overweight people has boosted with a consequent increase in obesity-related diseases. Considerable epidemiologic evidence correlates overweight and obese conditions to an increased risk of several types of cancer, including PDAC. Besides being a risk factor for multiple metabolic disorders, the tumor-promoting effects of obesity occur at the local level via inflammatory mediators that are associated with adipose inflammation and metabolic or hormones mediators and microbiota dysbiosis. Although an excess of body mass index (BMI) represents the second most modifiable risk factor for PDAC with an increased cancer related-death of more than 20⁻40%, still little is known about the molecular mechanisms that underlie this strong association. In this review, we focused on the role of obesity as a preventable risk factor of PDAC, discussing the molecular mechanisms linking obesity to cancer initiation and progression. Moreover, we highlighted the role of obesity in defining chemoresistance, showing how a high BMI can actually reduce response to chemotherapy.

KW - chemoresistance

KW - inflammation

KW - obesity

KW - pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=85055615464&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055615464&partnerID=8YFLogxK

U2 - 10.3390/ijms19113331

DO - 10.3390/ijms19113331

M3 - Review article

C2 - 30366466

AN - SCOPUS:85055615464

VL - 19

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 11

ER -